ANKRD30BP1: A Potential Drug Target and Biomarker (G642460)

Target Name: ANKRD30BP1

NCBI ID: G642460

ANKRD30BP1

Other Name(s): Ankyrin repeat domain 30B pseudogene 1 | ANKRD30BP | C21orf110 | ankyrin repeat domain 30B pseudogene 1 | PRED4

ANKRD30BP1: A Potential Drug Target and Biomarker

Ankyrin repeat domains are a type of gene mutation that has been identified in a variety of organisms, including humans. These domains are characterized by a repeated sequence of amino acids, which can give them unique structural features and functions. One such domain is the ANKRD30BP1 gene, which has been identified in the human genome.

The ANKRD30BP1 gene is located on chromosome 16 and encodes a protein known as ANKRD30BP1. This protein is a key regulator of the immune response and has been shown to play a role in a variety of biological processes, including responding to infection, inflammation, and damage.

One of the unique features of the ANKRD30BP1 protein is its ability to form anankyrin repeat, which is a type of structural domain that is characterized by a repeated sequence of amino acids. Anankyrin repeats have been identified in a variety of organisms, including humans, and have been shown to have a variety of functions, including modulating protein stability, interacting with other proteins, and participating in signaling pathways.

In the context of the ANKRD30BP1 gene, anankyrin repeats have been shown to be involved in the regulation of the immune response and in the development of autoimmune diseases. For example, studies have shown that ANKRD30BP1 mutations are associated with an increased risk of developing multiple sclerosis, an autoimmune disease that causes muscle weakness and fatigue.

In addition to its role in autoimmune diseases, ANKRD30BP1 has also been shown to be involved in a variety of other biological processes, including responding to infection, inflammation, and damage. For example, studies have shown that ANKRD30BP1 is involved in the regulation of cell death, and that it plays a role in the immune response by activating T cells.

Given the unique role that ANKRD30BP1 has been shown to play in a variety of biological processes, it is possible that it may be a drug target or biomarker. For example, studies have shown that ANKRD30BP1 mutations are associated with an increased risk of developing multiple sclerosis, and that ANKRD30BP1 has been shown to play a role in the regulation of cell death. These findings suggest that ANKRD30BP1 may be a promising target for new therapies.

In conclusion, ANKRD30BP1 is a gene mutation that has been identified in the human genome. It is characterized by a repeated sequence of amino acids and is involved in a variety of biological processes, including the immune response and cell death. Given its unique role in these processes, ANKRD30BP1 is a potential drug target or biomarker and has the potential to be a valuable tool in the development of new therapies.

Protein Name: Ankyrin Repeat Domain 30B Pseudogene 1

The "ANKRD30BP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD30BP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets